|
|
| | Encelimab Basic information |
| Product Name: | Encelimab | | Synonyms: | Encelimab;Research Grade Encelimab(DHD30404);Research Grade Encelimab;Encelimab (anti-LAG3) | | CAS: | 2173096-82-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Encelimab Structure]() |
| | Encelimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Encelimab Usage And Synthesis |
| Uses | Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft)[1]. | | References | [1] Perez-Santos M, et al. Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert Opin Drug Discov. 2022 Dec;17(12):1341-1355. DOI:10.1080/17460441.2022.2148652 |
| | Encelimab Preparation Products And Raw materials |
|